Metsera是一家减肥新药研发商，计划推多种药物进入临床，旨在推动药物研发和商业化进程，致力于为想要减肥的人群提供服务。近日，Metsera获得2.15亿美元B轮融资，Venrock Healthcare Capital Partners、Wellington Management联合领投，T. Rowe Price、Viking Global Investors、Deep Track Capi ...

此轮融资由Wellington Management和Venrock Healthcare Capital ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...

▎药明康德内容团队编辑2.15亿美元助力下一代肥胖和代谢疾病疗法开发Metsera公司今日宣布完成2.15亿美元的B轮融资。获得资金将用于加速其下一代肥胖和代谢疾病治疗药物的开发。该公司正在开展超长效、注射型GLP-1受体激动剂的2期临床试验。Met ...

NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...